PT-141 (Bremelanotide) + Thymosin Alpha-1 Stack: Evidence, Mechanism Overlap, and Protocol

What bremelanotide does on its own

Bremelanotide is a cyclic peptide of seven amino acids and a melanocortin receptor agonist. It activates several receptor subtypes, in this order of potency: MC1R, MC4R, MC3R, MC5R, MC2R. At the approved dose, binding at MC1R and MC4R is the most relevant [1]. How that translates into more sexual desire is unknown, and the label says so directly [1]. MC1R sits on pigment cells, so binding there increases pigmentation [1].

FDA approved bremelanotide on June 21, 2019 under NDA 210557; the current holder is Cosette Pharmaceuticals [1][3]. The approved use is narrow: premenopausal women with acquired, generalized hypoactive sexual desire disorder, meaning low desire that developed in a woman who previously had no problem, occurs regardless of stimulation, situation or partner, and is not explained by another medical or psychiatric condition, relationship problems, or a drug [1]. The label states it is not indicated for men, for postmenopausal women, or to enhance sexual performance [1].

The labeled dose is 1.75 mg injected subcutaneously into the abdomen or thigh with an autoinjector, at least 45 minutes before anticipated sexual activity. The label says not to use more than one dose within 24 hours and that more than 8 doses per month is not recommended. It also says to stop after 8 weeks if there is no improvement in symptoms. How long a single dose keeps working is unknown [1].

What thymosin alpha-1 does on its own

Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide with an acetylated N-terminal end, originally isolated from thymosin fraction 5, a thymus extract. Thymalfasin is the synthetic version with the same sequence. Zadaxin is the finished 1.6 mg injection sold outside the US and is not interchangeable with bulk peptide powder [2]. It is described as an immune modulator that augments T-cell function [6]. In healthy volunteers given a subcutaneous dose, it peaks at roughly 0.7 to 2 hours, clears with a half-life of about 1.8 to 2.6 hours, and did not accumulate over five daily doses [6][2].

In laboratory work reported in Blood in 2006, thymosin alpha-1 primed dendritic cells through Toll-like receptor 9 signaling. In mouse dendritic cells it also induced indoleamine 2,3-dioxygenase, which led to interleukin-10 production and regulatory T cells. The authors described the result as T-helper type 1 immunity established within a regulatory environment [5].

Do the two interact?

The Vyleesi label's drug interaction section covers two things. First, bremelanotide may slow stomach emptying and reduce absorption of oral medicines; the label says to avoid Vyleesi with oral drugs that depend on threshold blood concentrations, such as antibiotics. Second, it may significantly lower exposure to oral naltrexone, and the label says to avoid using the two together when naltrexone is for alcohol or opioid addiction [1]. Both concerns involve oral medicines. Thymosin alpha-1 is given by injection [2], and the label's interaction section does not name it [1]. That silence does not show the two are free of interaction, and no study has examined the question.

Where the mechanisms might overlap

The named targets do not overlap. Bremelanotide's are the melanocortin receptors [1]. Thymosin alpha-1's described action runs through dendritic-cell Toll-like receptor 9 signaling and T-cell function [5][6]. Each is described in its own literature against its own target, and neither body of work examines the other.

There is a family resemblance that often gets stretched further than the data allow. Bremelanotide is a synthetic analogue of alpha-melanocyte-stimulating hormone [7], and melanocortin peptides as a group show anti-inflammatory and immunomodulatory effects in laboratory and animal work [8]. That is a property of the melanocortin family in preclinical models. It is not a measured effect of a 1.75 mg Vyleesi dose in people, and it does not establish that the approved dose changes any immune measure.

What the Vyleesi label says to watch for

Each dose transiently raises blood pressure and lowers heart rate. In clinical studies the maximal increases were 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with a heart rate fall of up to 5 beats per minute; values usually returned to baseline within 12 hours [1]. In a separate ambulatory study of 127 premenopausal women dosed once daily for 8 days, the mean daytime increase was 1.9 mmHg systolic and 1.7 mmHg diastolic, with a mean heart rate decrease of 0.5 beats per minute [1]. The 6/3 figures are maximal increases; these are mean increases. Vyleesi is contraindicated in uncontrolled hypertension or known cardiovascular disease and is not recommended for people at high risk of cardiovascular disease [1].

Nausea was reported by 40% of Vyleesi patients versus 1.3% on placebo; 13% needed anti-nausea medicine and 8% stopped the trials because of it. It was highest after the first dose, at 21%, and fell to about 3% with later doses. Pre-treating with oral ondansetron 30 minutes before the injection did not reduce nausea in a phase 4 study of 228 healthy women, and the label does not recommend it [1].

Focal hyperpigmentation, including on the face, gums and breasts, was reported by 1% of patients using up to 8 doses a month in the phase 3 trials, versus none on placebo. In a separate study, 38% developed it after daily dosing for 8 days, and another 14% after 8 more consecutive days. Resolution was not confirmed in every patient [1]. Vyleesi carries no boxed warning and no REMS [1][3].

What is known about thymosin alpha-1 safety

FDA searched its adverse-event database on April 22, 2024 and found zero reports for thymosin alpha-1 [2]. A 2026 Cochrane review of hepatitis B trials found the peptide may have caused fewer serious adverse events than comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low-certainty evidence) and fewer non-serious events (RR 0.47, 95% CI 0.27 to 0.83; very low-certainty evidence) [4].

FDA's compounding page still posts its safety concerns about the bulk substance: significant immunogenicity risk for certain routes of administration, peptide-impurity and characterization problems, and safety information that is inadequate for the agency to understand the extent of any safety issues [9].

How strong is the thymosin alpha-1 evidence itself?

The 2026 Cochrane review pooled 10 randomized trials with 1,349 adults, published 1991 to 2018, testing thymosin alpha-1 in chronic hepatitis B. It found possible lower all-cause mortality (RR 0.53, 95% CI 0.29 to 0.96; 3 trials, 907 people) at very low certainty, little to no effect on quality of life or liver histology, and a very uncertain effect on hepatitis B-related illness. The reviewers said they were not sure the drug helps [4].

Individual trials are small. In a double-blind trial of 98 adults, adding thymosin alpha-1 to lymphoblastoid interferon for 24 weeks produced HBeAg loss at 72 weeks of 45.8% versus 28.0% (difference 17.8%, 95% CI -1.2 to 35.3, P=0.067), which did not reach statistical significance [10]. A 1991 placebo-controlled pilot enrolled 12 people [11].

Regulatory status of each product

Vyleesi is the FDA-approved bremelanotide product. Products sold as compounded or research-use PT-141 are not Vyleesi and are not FDA-approved drugs, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [12][1][13]. HealthRX.com's PT-141 page is the place for details on that product; only Vyleesi is the FDA-approved bremelanotide product [12].

FDA's search found no US application for thymosin alpha-1. Four orphan drug designations exist, but orphan designation is a separate process and is not an approval [2]. It is authorized in Italy as an adjuvant to influenza vaccination in immunocompromised people, in India for chronic hepatitis B in adults with compensated liver disease and viral replication, and in Hong Kong [2]. Two reviews by authors tied to the product's developer put the figure at more than 30 or over 35 countries [14][15]. The European Medicines Agency has granted only an orphan designation for hepatocellular carcinoma [2].

FDA's advisory committee voted 4 yes and 17 no, with no abstentions, on whether to add thymosin alpha-1 to the pharmacy bulk substances list in December 2024 [16]. The peptide came off the significant-safety-risk category because the nominators withdrew it, and FDA's concerns remain posted [9]. It is not covered by FDA's category 1 policy, sits in category 3 (nominated without adequate support) on the outsourcing facility list, and is not one of the six peptides in the October 2026 HHS enforcement-discretion draft [17][18][19].

Neither peptide is named on WADA's 2026 Prohibited List. WADA does name thymosin beta-4 and derivatives such as TB-500, which is a different peptide [20].

Is there a tested protocol for the stack?

We found no tested protocol for this combination. The Vyleesi label's dosing applies to its approved use in premenopausal women with HSDD [1]. The Italian Zadaxin schedule applies to use with influenza vaccination [2]. In a 2006 hepatitis B trial, thymosin alpha-1 was added three times weekly for 24 weeks to lymphoblastoid interferon [10]. None of these schedules was designed or tested for the two peptides together.